ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Senior Director, Manufacturing at Lyell Immunopharma - ApplyBlast

Senior Director, Manufacturing

Lyell Immunopharma

3 days ago

3.1 on Glassdoor

Bothell, Washington, United States

Onsite

Full Time

Director

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

The Senior Director of Manufacturing leads the cell therapy manufacturing organization through the transition from clinical-stage to commercial operations. This hands-on leadership role oversees GMP manufacturing execution across the product lifecycle, ensuring facility and process readiness for BLA submission and pre-license inspection. The position involves building a scalable, inspection-ready commercial manufacturing organization and driving operational excellence.

Responsibilities

Lead manufacturing readiness for BLA filing, PLI, and commercial launch
Direct day-to-day clinical and commercial manufacturing operations
Build and mentor a high-performing manufacturing organization

Skills

Qualifications

BA/BSc in Molecular Biology, Immunology, Biotechnology or related disciplineMBA or MSc in Molecular Biology, Immunology, Biotechnology or related discipline

About Lyell Immunopharma

lyell.com

Headquarters

South San Francisco, California, United States

Company Size

201-500 employees

Founded

2018

View Profile

Lyell is a fully integrated biopharmaceutical company developing next‑generation T‑cell reprogramming technologies to create durable CAR T‑cell therapies for hematologic malignancies and solid tumors. Their platform-driven approach spans discovery through clinical development, with active programs and trials such as the PiNACLE study for aggressive B‑cell non‑Hodgkin lymphoma and the recently acquired GCC‑targeted candidate LYL273. Lyell is patient‑focused, aiming to improve outcomes for cancers with significant unmet medical need.